Allogene Therapeutics reports Q3 2026 net loss of $50.4 million
ALLO•Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million. It had $388.9 million in cash, cash equivalents and investments at September 30, with a projected cash runway into 2029.
1. Quarterly results and outlook
Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million and said cash, cash equivalents and investments totaled $388.9 million at September 30, supporting a projected cash runway into 2029. The company projected 2026 GAAP operating expenses of approximately $225 million, including about $35 million in non-cash stock-based compensation. An ALPHA3 clinical update is expected in mid-2027, with enrollment completion anticipated by year-end 2027; updated ALLO-329 trial results are scheduled for presentation November 9, 2026.
